isoniazid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1497 54-85-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • isoniazid
  • 4-Pyridinecarboxylic hydrazide
  • armazid
  • isoniazide
  • isonicotinohydrazide
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
  • Molecular weight: 137.14
  • Formula: C6H7N3O
  • CLOGP: -0.67
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 68.01
  • ALOGS: -0.59
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 153 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 72.92 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.82 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 29, 1952 FDA SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 595.92 13.51 273 18536 29275 46637978
Drug-induced liver injury 454.35 13.51 216 18593 25152 46642101
Tuberculosis 400.57 13.51 152 18657 10113 46657140
Paradoxical drug reaction 380.11 13.51 103 18706 2273 46664980
Acute hepatic failure 337.82 13.51 149 18660 14572 46652681
Hepatotoxicity 241.58 13.51 141 18668 24868 46642385
Drug resistance 236.96 13.51 123 18686 17245 46650008
Hepatitis 235.50 13.51 152 18657 32063 46635190
Pulmonary tuberculosis 228.54 13.51 82 18727 4649 46662604
Tuberculoma of central nervous system 191.85 13.51 40 18769 263 46666990
Jaundice 188.68 13.51 127 18682 28718 46638535
Disseminated tuberculosis 164.83 13.51 56 18753 2696 46664557
Immune reconstitution inflammatory syndrome associated tuberculosis 159.73 13.51 36 18773 355 46666898
Hepatic encephalopathy 150.28 13.51 76 18733 10081 46657172
Immune reconstitution inflammatory syndrome 144.47 13.51 62 18747 5663 46661590
Drug interaction 129.14 13.51 265 18544 202829 46464424
Pyrexia 126.24 13.51 366 18443 348436 46318817
Liver injury 113.17 13.51 74 18735 15927 46651326
Transaminases increased 92.68 13.51 82 18727 27679 46639574
Hepatic failure 90.82 13.51 88 18721 33328 46633925
Cerebellar ataxia 89.64 13.51 27 18782 877 46666376
Hepatocellular injury 86.41 13.51 81 18728 29441 46637812
Hepatic function abnormal 84.94 13.51 86 18723 34335 46632918
Lymph node tuberculosis 84.68 13.51 25 18784 757 46666496
Eosinophilia 83.27 13.51 66 18743 19151 46648102
Alanine aminotransferase increased 78.05 13.51 133 18676 88318 46578935
Lymphadenopathy 77.80 13.51 81 18728 33407 46633846
Aspartate aminotransferase increased 72.97 13.51 121 18688 78579 46588674
Hepatitis fulminant 70.21 13.51 32 18777 3370 46663883
Tuberculin test positive 64.35 13.51 29 18780 2975 46664278
Exposure during pregnancy 61.41 13.51 135 18674 108077 46559176
Encephalopathy 60.31 13.51 71 18738 33518 46633735
Tuberculosis gastrointestinal 59.32 13.51 16 18793 346 46666907
Pneumocystis jirovecii pneumonia 58.94 13.51 49 18760 15199 46652054
Loss of employment 57.76 13.51 21 18788 1235 46666018
Peritoneal tuberculosis 56.92 13.51 17 18792 536 46666717
Mycobacterium tuberculosis complex test positive 56.62 13.51 22 18787 1556 46665697
Meningitis tuberculous 56.15 13.51 17 18792 562 46666691
Tuberculosis of central nervous system 54.05 13.51 15 18794 362 46666891
Latent tuberculosis 52 13.51 22 18787 1938 46665315
Pain 47.92 13.51 74 18735 476874 46190379
Liver transplant 47.57 13.51 22 18787 2395 46664858
Generalised tonic-clonic seizure 46.49 13.51 56 18753 27066 46640187
Liver disorder 43.90 13.51 64 18745 37182 46630071
Fatigue 43.60 13.51 115 18694 608582 46058671
Glomerulonephritis minimal lesion 43.55 13.51 11 18798 182 46667071
Rash maculo-papular 38.97 13.51 52 18757 27822 46639431
Hepatitis toxic 37.34 13.51 20 18789 2980 46664273
Fall 37.04 13.51 47 18762 329050 46338203
Product dose omission issue 35.18 13.51 12 18797 168508 46498745
Coagulopathy 33.02 13.51 39 18770 18460 46648793
Focal dyscognitive seizures 32.83 13.51 18 18791 2810 46664443
Hepatic necrosis 32.67 13.51 23 18786 5578 46661675
Hepatosplenomegaly 32.64 13.51 17 18792 2393 46664860
Serpiginous choroiditis 32.59 13.51 6 18803 18 46667235
Bovine tuberculosis 32.15 13.51 7 18802 58 46667195
Hepatic haematoma 30.73 13.51 10 18799 420 46666833
Tuberculous pleurisy 30.42 13.51 10 18799 434 46666819
Choroiditis 30.39 13.51 8 18801 157 46667096
Myocarditis 30.17 13.51 25 18784 7714 46659539
Hypertransaminasaemia 29.32 13.51 18 18791 3470 46663783
Serotonin syndrome 29.09 13.51 42 18767 24178 46643075
Face oedema 28.74 13.51 37 18772 19116 46648137
C-reactive protein increased 26.55 13.51 67 18742 58523 46608730
Multiple-drug resistance 26.17 13.51 15 18794 2550 46664703
Hemianopia heteronymous 26.11 13.51 6 18803 65 46667188
Immune system disorder 25.45 13.51 23 18786 7972 46659281
Jarisch-Herxheimer reaction 25.35 13.51 8 18801 304 46666949
Drug level decreased 24.95 13.51 20 18789 5892 46661361
Neurotoxicity 24.62 13.51 29 18780 13688 46653565
Aspergillus infection 24.28 13.51 21 18788 6869 46660384
Liver function test abnormal 24.10 13.51 56 18753 46431 46620822
Lupus-like syndrome 23.86 13.51 22 18787 7822 46659431
Ocular icterus 23.71 13.51 16 18793 3624 46663629
Microcytic anaemia 23.55 13.51 15 18794 3083 46664170
Hepatic enzyme increased 23.09 13.51 79 18730 81708 46585545
Interstitial lung disease 22.70 13.51 60 18749 53889 46613364
Trichophytosis 22.30 13.51 5 18804 48 46667205
Death 21.99 13.51 66 18743 335482 46331771
Anxiety 21.48 13.51 25 18784 181932 46485321
Pericarditis tuberculous 21.04 13.51 4 18805 15 46667238
Gamma-glutamyltransferase increased 20.76 13.51 42 18767 31698 46635555
Hepatitis B core antibody positive 20.57 13.51 6 18803 174 46667079
Pleural effusion 19.91 13.51 76 18733 82876 46584377
Hyperinsulinaemia 19.90 13.51 5 18804 81 46667172
Feeling abnormal 19.81 13.51 13 18796 125047 46542206
Blood bilirubin increased 19.75 13.51 43 18766 34141 46633112
Central venous pressure increased 19.62 13.51 5 18804 86 46667167
Liver transplant rejection 19.43 13.51 10 18799 1373 46665880
Diarrhoea 19.43 13.51 139 18670 559463 46107790
Nephrotic syndrome 19.40 13.51 16 18793 4905 46662348
Muscle spasms 19.23 13.51 13 18796 123100 46544153
Rash morbilliform 19.06 13.51 13 18796 2996 46664257
Vomiting 18.89 13.51 271 18538 452523 46214730
Blood beta-D-glucan increased 18.65 13.51 6 18803 243 46667010
Granuloma 18.53 13.51 14 18795 3784 46663469
Lymphadenitis 18.29 13.51 12 18797 2593 46664660
Joint tuberculosis 18.28 13.51 5 18804 114 46667139
Substance-induced psychotic disorder 18.24 13.51 10 18799 1560 46665693
Cerebrovascular accident 18.15 13.51 9 18800 101030 46566223
Mycobacterial infection 17.87 13.51 10 18799 1623 46665630
Pneumonia lipoid 17.59 13.51 5 18804 132 46667121
Stillbirth 17.44 13.51 17 18792 6474 46660779
Hepatic steatosis 17.15 13.51 33 18776 24009 46643244
Optic neuropathy 16.99 13.51 10 18799 1786 46665467
Cytomegalovirus infection 16.93 13.51 28 18781 18116 46649137
Immunosuppressant drug level decreased 16.85 13.51 8 18801 924 46666329
Toxic optic neuropathy 16.82 13.51 5 18804 155 46667098
Acute respiratory distress syndrome 16.77 13.51 31 18778 21891 46645362
Drug level increased 16.59 13.51 28 18781 18413 46648840
Chromaturia 16.53 13.51 25 18784 14994 46652259
Pathogen resistance 16.53 13.51 16 18793 6044 46661209
Constipation 16.48 13.51 28 18781 174069 46493184
Depression 16.43 13.51 27 18782 170077 46497176
Hepatic cyst 15.74 13.51 14 18795 4752 46662501
Mycobacterium avium complex infection 15.74 13.51 11 18798 2637 46664616
Cholestatic liver injury 15.59 13.51 10 18799 2080 46665173
Bilirubin conjugated increased 15.55 13.51 11 18798 2687 46664566
Organising pneumonia 15.40 13.51 14 18795 4888 46662365
Drug hypersensitivity 15.22 13.51 49 18760 243776 46423477
Transplant rejection 15.12 13.51 19 18790 9577 46657676
Liver palpable 14.92 13.51 3 18806 16 46667237
Optic neuritis 14.84 13.51 16 18793 6855 46660398
Granulomatous dermatitis 14.24 13.51 4 18805 101 46667152
Completed suicide 14.24 13.51 23 18786 145897 46521356
Sinusitis 14.08 13.51 19 18790 129749 46537504
Contusion 13.98 13.51 9 18800 87478 46579775
Hyperuricaemia 13.90 13.51 13 18796 4704 46662549
Toxoplasmosis 13.81 13.51 8 18801 1386 46665867
Antipsychotic drug level above therapeutic 13.79 13.51 7 18802 934 46666319
Encephalitis 13.79 13.51 16 18793 7432 46659821
Paraparesis 13.78 13.51 9 18800 1930 46665323
Memory impairment 13.72 13.51 7 18802 77330 46589923
Status epilepticus 13.62 13.51 22 18787 13957 46653296
Mycoplasma genitalium infection 13.56 13.51 3 18806 27 46667226
Central nervous system immune reconstitution inflammatory response 13.56 13.51 3 18806 27 46667226

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 787.91 13.79 205 18217 2457 29931599
Tuberculosis 461.23 13.79 177 18245 7900 29926156
Drug-induced liver injury 406.66 13.79 217 18205 21057 29912999
Drug reaction with eosinophilia and systemic symptoms 388.70 13.79 233 18189 28255 29905801
Immune reconstitution inflammatory syndrome 365.98 13.79 155 18267 8946 29925110
Hepatotoxicity 326.88 13.79 178 18244 17967 29916089
Jaundice 293.21 13.79 205 18217 32281 29901775
Pulmonary tuberculosis 275.60 13.79 106 18316 4751 29929305
Drug resistance 219.70 13.79 143 18279 19990 29914066
Hepatitis 187.52 13.79 135 18287 22221 29911835
Immune reconstitution inflammatory syndrome associated tuberculosis 181.85 13.79 44 18378 381 29933675
Tuberculoma of central nervous system 176.05 13.79 40 18382 255 29933801
Disseminated tuberculosis 145.18 13.79 53 18369 2049 29932007
Meningitis tuberculous 117.64 13.79 33 18389 532 29933524
Pyrexia 92.22 13.79 391 18031 294098 29639958
Immune system disorder 91.18 13.79 47 18375 4230 29929826
Acute hepatic failure 89.14 13.79 67 18355 11760 29922296
Serpiginous choroiditis 75.83 13.79 16 18406 68 29933988
Drug interaction 74.34 13.79 280 18142 199288 29734768
Latent tuberculosis 69.90 13.79 25 18397 910 29933146
Alanine aminotransferase increased 69.59 13.79 146 18276 74130 29859926
Lymph node tuberculosis 68.95 13.79 21 18401 457 29933599
Death 68.00 13.79 72 18350 357211 29576845
Optic neuritis 64.53 13.79 34 18388 3200 29930856
Hepatic function abnormal 64.17 13.79 102 18320 41843 29892213
Tuberculosis of central nervous system 63.69 13.79 16 18406 164 29933892
Granuloma 61.95 13.79 30 18392 2362 29931694
Hepatitis toxic 59.49 13.79 28 18394 2069 29931987
Hepatic failure 59.41 13.79 88 18334 33955 29900101
Lymphadenopathy 57.64 13.79 73 18349 24303 29909753
Liver function test abnormal 56.90 13.79 82 18340 30868 29903188
Fall 55.96 13.79 21 18401 181851 29752205
Hepatic enzyme increased 54.77 13.79 84 18338 33410 29900646
Bone tuberculosis 54.18 13.79 16 18406 312 29933744
Hepatitis fulminant 50.45 13.79 31 18391 3910 29930146
Tubulointerstitial nephritis 49.47 13.79 58 18364 17833 29916223
Aspartate aminotransferase increased 48.50 13.79 115 18307 63307 29870749
Hydrocephalus 48.39 13.79 31 18391 4206 29929850
Tuberculous pleurisy 47.70 13.79 15 18407 364 29933692
Skin disorder 46.88 13.79 46 18376 11562 29922494
Tuberculosis gastrointestinal 41.75 13.79 12 18410 212 29933844
Transaminases increased 41.43 13.79 61 18361 23396 29910660
Demodicidosis 41.33 13.79 11 18411 144 29933912
Optic neuropathy 40.66 13.79 20 18402 1629 29932427
Tuberculosis of eye 39.37 13.79 8 18414 27 29934029
Peritoneal tuberculosis 38.70 13.79 13 18409 391 29933665
Mycobacterium tuberculosis complex test positive 37.37 13.79 16 18406 945 29933111
Tuberculin test positive 36.90 13.79 16 18406 975 29933081
Granulomatous liver disease 35.84 13.79 13 18409 493 29933563
Drug level decreased 35.33 13.79 29 18393 5776 29928280
Hepatocellular injury 34.95 13.79 59 18363 25412 29908644
Bovine tuberculosis 33.26 13.79 9 18413 126 29933930
Type III immune complex mediated reaction 31.83 13.79 10 18412 242 29933814
Drug eruption 31.56 13.79 46 18376 17480 29916576
Eosinophilia 31.30 13.79 52 18370 22108 29911948
Optic atrophy 30.44 13.79 13 18409 763 29933293
Disseminated Bacillus Calmette-Guerin infection 30.04 13.79 8 18414 105 29933951
Liver disorder 29.64 13.79 60 18362 29662 29904394
Toxic epidermal necrolysis 29.32 13.79 45 18377 17895 29916161
Colour blindness 28.60 13.79 9 18413 219 29933837
Myocardial infarction 27.71 13.79 22 18400 125603 29808453
Liver injury 27.52 13.79 36 18386 12364 29921692
Blood bilirubin increased 27.51 13.79 66 18356 36570 29897486
Completed suicide 26.60 13.79 14 18408 99478 29834578
Condition aggravated 26.54 13.79 160 18262 137706 29796350
Atrial fibrillation 26.38 13.79 17 18405 108107 29825949
Splenic abscess 26.06 13.79 9 18413 295 29933761
Hyperuricaemia 25.66 13.79 27 18395 7367 29926689
Lichenoid keratosis 25.61 13.79 16 18406 2078 29931978
Extrapulmonary tuberculosis 25.36 13.79 7 18415 106 29933950
Mycobacterium fortuitum infection 25.33 13.79 8 18414 197 29933859
Diarrhoea 25.15 13.79 113 18309 333990 29600066
Cholestasis 24.44 13.79 50 18372 24900 29909156
Pain 24.42 13.79 43 18379 172598 29761458
Product dose omission issue 24.34 13.79 13 18409 91618 29842438
Papilloma 24.33 13.79 7 18415 124 29933932
Hepatic encephalopathy 23.76 13.79 36 18386 14156 29919900
Bilirubin conjugated increased 23.08 13.79 18 18404 3333 29930723
Multiple-drug resistance 22.90 13.79 17 18405 2924 29931132
Oral candidiasis 22.81 13.79 31 18391 11040 29923016
Rash maculo-papular 22.64 13.79 49 18373 25369 29908687
Hypotension 22.47 13.79 57 18365 200508 29733548
Dermatitis exfoliative 22.00 13.79 25 18397 7431 29926625
Papule 21.95 13.79 17 18405 3116 29930940
Ocular toxicity 21.84 13.79 7 18415 181 29933875
Pericarditis tuberculous 21.20 13.79 6 18416 100 29933956
Diaphragmatic injury 21.12 13.79 5 18417 39 29934017
Malignant neoplasm progression 21.12 13.79 9 18413 72278 29861778
Erythrodermic psoriasis 21.08 13.79 10 18412 752 29933304
Tuberculosis of genitourinary system 20.90 13.79 5 18417 41 29934015
Hepatic necrosis 20.83 13.79 18 18404 3845 29930211
Mycobacterial infection 20.67 13.79 13 18409 1708 29932348
Transient aphasia 20.46 13.79 6 18416 114 29933942
Red man syndrome 20.24 13.79 10 18412 822 29933234
Unmasking of previously unidentified disease 20.15 13.79 9 18413 589 29933467
Central nervous system vasculitis 20.12 13.79 8 18414 391 29933665
Liver transplant rejection 20.08 13.79 14 18408 2184 29931872
Encephalopathy 20.00 13.79 54 18368 32151 29901905
Complications of transplanted kidney 19.90 13.79 18 18404 4083 29929973
Tuberculoid leprosy 19.84 13.79 5 18417 52 29934004
Chronic allograft nephropathy 19.75 13.79 11 18411 1155 29932901
Cardiac failure congestive 19.61 13.79 14 18408 84393 29849663
Mitochondrial neurogastrointestinal encephalopathy 19.57 13.79 4 18418 14 29934042
Dilatation intrahepatic duct acquired 19.50 13.79 5 18417 56 29934000
Pulmonary sequestration 19.42 13.79 5 18417 57 29933999
Thalamic infarction 19.42 13.79 9 18413 642 29933414
Tuberculosis liver 19.04 13.79 5 18417 62 29933994
Constipation 18.96 13.79 25 18397 112881 29821175
Trisomy 21 18.90 13.79 8 18414 459 29933597
Anaplastic astrocytoma 18.58 13.79 6 18416 159 29933897
Feeling abnormal 18.36 13.79 6 18416 56750 29877306
Dyspnoea 18.33 13.79 125 18297 333170 29600886
Granulomatous lymphadenitis 18.28 13.79 5 18417 73 29933983
Ototoxicity 17.92 13.79 11 18411 1385 29932671
Cryptococcosis 17.70 13.79 12 18410 1790 29932266
Cachexia 17.55 13.79 21 18401 6590 29927466
Fatigue 17.27 13.79 121 18301 320552 29613504
Liver transplant 17.06 13.79 14 18408 2788 29931268
Psoas abscess 16.98 13.79 8 18414 592 29933464
Hemianopia heteronymous 16.59 13.79 4 18418 34 29934022
Genitourinary tract infection 16.58 13.79 5 18417 105 29933951
Coronary artery disease 16.54 13.79 5 18417 49707 29884349
Past-pointing 16.49 13.79 4 18418 35 29934021
Protrusion tongue 16.45 13.79 6 18416 231 29933825
Pneumocystis jirovecii pneumonia 16.40 13.79 34 18388 17086 29916970
Spermatozoa progressive motility abnormal 16.20 13.79 4 18418 38 29934018
Testicular mass 15.87 13.79 5 18417 122 29933934
Herpes zoster meningoencephalitis 15.78 13.79 6 18416 260 29933796
Leprosy 15.68 13.79 5 18417 127 29933929
Spermatozoa progressive motility decreased 15.43 13.79 5 18417 134 29933922
Urogenital infection bacterial 15.35 13.79 4 18418 48 29934008
Insomnia 15.32 13.79 21 18401 93315 29840741
Myxoedema coma 15.12 13.79 6 18416 292 29933764
Cell death 15.02 13.79 12 18410 2299 29931757
Vaccination failure 14.86 13.79 5 18417 151 29933905
Encephalitis 14.77 13.79 19 18403 6417 29927639
Chronic obstructive pulmonary disease 14.71 13.79 5 18417 46121 29887935
Vasculitis 14.42 13.79 21 18401 7969 29926087
Chorioretinitis 14.30 13.79 5 18417 170 29933886
Hypermetabolism 14.30 13.79 5 18417 170 29933886
Cardiac arrest 14.16 13.79 22 18400 92828 29841228
Mycobacterium abscessus infection 14.10 13.79 7 18415 581 29933475
Face oedema 13.91 13.79 25 18397 11309 29922747

Pharmacologic Action:

SourceCodeDescription
ATC J04AC01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Hydrazides
ATC J04AC51 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Hydrazides
ATC J04AM01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM08 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
FDA EPC N0000175483 Antimycobacterial
CHEBI has role CHEBI:33231 antitubercular
CHEBI has role CHEBI:88188 allergenic drug
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000963 Antimetabolites
MeSH PA D000995 Antitubercular Agents
MeSH PA D054872 Fatty Acid Synthesis Inhibitors
MeSH PA D000960 Hypolipidemic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Inactive tuberculosis indication 11999007
Acute tuberculosis indication 25629007
Pulmonary tuberculosis indication 154283005 DOID:2957
Tuberculosis of meninges off-label use 58437007
Atypical mycobacterial infection off-label use 111812000
Nutritional disorder contraindication 2492009 DOID:374
Alcoholism contraindication 7200002
Jaundice contraindication 18165001
Acute hepatitis contraindication 37871000
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Gout contraindication 90560007 DOID:13189
Anemia due to enzyme deficiency contraindication 111577008
Acute hepatic failure contraindication 197270009
Disease of liver contraindication 235856003 DOID:409
Diabetic - poor control contraindication 268519009
Peripheral nerve disease contraindication 302226006
Porphyria contraindication 418470004
Diabetic peripheral neuropathy contraindication 424736006
Slow acetylator due to N-acetyltransferase enzyme variant contraindication 425079005
Prolonged-Severe Nausea and Vomiting contraindication
Chronic Hepatic Disease contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.98 acidic
pKa2 3.79 Basic
pKa3 1.94 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cytochrome P450 3A4 Enzyme IC50 5.31 WOMBAT-PK
Cytochrome P450 3A5 Enzyme IC50 4.96 WOMBAT-PK
Enoyl-[acyl-carrier-protein] reductase [NADH] Enzyme INHIBITOR WOMBAT-PK CHEMBL
Catalase-peroxidase Enzyme WOMBAT-PK
Dihydrofolate reductase Enzyme Ki 9 CHEMBL

External reference:

IDSource
4017505 VUID
N0000145890 NUI
D00346 KEGG_DRUG
4017505 VANDF
C0022209 UMLSCUI
CHEBI:6030 CHEBI
NIZ PDB_CHEM_ID
3767 PUBCHEM_CID
CHEMBL64 ChEMBL_ID
DB00951 DRUGBANK_ID
D007538 MESH_DESCRIPTOR_UI
4188 INN_ID
V83O1VOZ8L UNII
6038 RXNORM
2955 MMSL
4929 MMSL
d00101 MMSL
002844 NDDF
387472004 SNOMEDCT_US
81335000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 0440-1655 TABLET 300 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 0440-7655 TABLET 300 mg ORAL ANDA 22 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 0527-1109 TABLET 300 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 0555-0066 TABLET 100 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 0555-0071 TABLET 300 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 0781-3056 INJECTION, SOLUTION 100 mg INTRAMUSCULAR ANDA 25 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 10135-584 TABLET 300 mg ORAL ANDA 22 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 10544-087 TABLET 300 mg ORAL ANDA 23 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 10544-121 TABLET 300 mg ORAL ANDA 23 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 10544-218 TABLET 300 mg ORAL ANDA 22 sections
ISONIAZID HUMAN PRESCRIPTION DRUG LABEL 1 16590-984 TABLET 300 mg ORAL ANDA 13 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 21695-627 TABLET 300 mg ORAL ANDA 22 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 43063-463 TABLET 300 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 46287-009 SOLUTION 50 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 50090-0370 TABLET 300 mg ORAL ANDA 23 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 50090-0370 TABLET 300 mg ORAL ANDA 23 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 50090-0410 TABLET 100 mg ORAL ANDA 23 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 50090-1490 SOLUTION 50 mg ORAL ANDA 23 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 51079-083 TABLET 300 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 51655-391 TABLET 300 mg ORAL ANDA 10 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 52959-145 TABLET 300 mg ORAL ANDA 22 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 53002-2920 TABLET 300 mg ORAL ANDA 23 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 53808-1041 TABLET 300 mg ORAL ANDA 23 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 54868-2304 TABLET 100 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 54868-2416 TABLET 300 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 55695-027 TABLET 100 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 55695-031 SOLUTION 50 mg ORAL ANDA 25 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 55695-033 TABLET 300 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 60687-553 TABLET 300 mg ORAL ANDA 24 sections
Isoniazid HUMAN PRESCRIPTION DRUG LABEL 1 61748-013 TABLET 300 mg ORAL ANDA 23 sections